SoftMaxx AI sells no peptides and takes no vendor money.
No supporting study We found no study that compared facial volume or shape in people taking semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) with a control group. The commentaries cited here tie "Ozempic face" to rapid weight loss, and one asks whether it is a new drug effect at all.[1][2]
The tier describes the evidence for GLP-1 drugs' effect on face shape; stronger evidence on this page concerns drug-label side effects and one uncontrolled imaging study of midface volume.
The short answer
| Question | What we found |
|---|---|
| Do semaglutide or tirzepatide change the face itself? | We found no study with a control group that measured it |
| What is "Ozempic face"? | A media term; commentaries tie it to rapid weight loss [1][2] |
| What do the drug labels list? | Hair loss, more often than on placebo, which each label associates with weight reduction [3][4][5] |
| Can I see changes in my own face? | Only by measuring it the same way each time; see the last section |
This page shows no before-and-after photos.
- Common belief
Ozempic changes the shape of your face
No supporting study We found no study that compared facial volume or shape in people on semaglutide or tirzepatide with a control group. The two commentary abstracts cited here report no facial measurements, and a 2024 letter on the topic has no abstract on PubMed. Our search also found a 2025 imaging study of 20 patients that measured midface volume on medical scans and describes no control group [6], and two systematic reviews [7] [8]; they are summarized in the commentaries section below.[1][2][9]
What the drug labels list
The FDA labels for Wegovy (semaglutide), Zepbound (tirzepatide) and Foundayo (orforglipron) list hair loss among their common adverse reactions, and each says hair loss was associated with weight reduction [3][4][5].
| Label | Hair loss on the drug | On placebo |
|---|---|---|
| Wegovy (semaglutide) | 3.3% in a pool of three trials | 1% [3] |
| Zepbound (tirzepatide) | 4% to 5% across the strengths tested | 1% [4] |
| Foundayo (orforglipron) | 4% to 5% across the strengths tested | 2% [5] |
We found no description of a change in facial shape or volume in the three labels. The face appears on them only in the warning about serious allergic reactions, which lists swelling of the face, lips, tongue or throat.
Foundayo is a daily tablet, and orforglipron is not a peptide: a 2024 paper on how it works describes it as a nonpeptide GLP-1 receptor agonist [10].
- Drug label Wegovy label: in a pool of three trials, hair loss was reported in 3.3% of people on Wegovy (4% of women, 0.9% of men) and 1% on placebo; in trials of its highest-strength pen, 5.8% versus 1.0%. The label says hair loss was associated with weight reduction.[3]
- Drug label Zepbound label: hair loss was reported in 4% to 5% of people across the strengths tested versus 1% on placebo, and more often in women (7.1%) than in men (0.5%).[4]
- Drug label Foundayo label: hair loss was reported in 4% to 5% of people across the strengths tested versus 2% on placebo, in 7% of women and 0.9% of men on the drug.[5]
- Drug label All three labels list swelling of the face, lips, tongue or throat as a sign of a serious allergic reaction, with the instruction to stop the medicine and get medical help right away.[3][4][5]
What weight loss can do to a face: the commentaries
We found no study that compared facial volume after weight loss on these drugs with facial volume after the same weight loss without them. The sources below are two commentaries, a letter, a procedure report, one imaging study without a control group and two systematic reviews; we found no measured comparison with a control group among them.
- Expert review A 2023 commentary addressed to facial plastic surgeons says rapid weight loss on Ozempic can deplete facial volume and fat, leaving wrinkles and sagging skin, and that prescribers seldom counsel patients about the face.[1]
- Common belief
"Ozempic face" is a special effect of the drug
Expert review A 2024 commentary calls "Ozempic face" a new purported side effect describing rapid facial weight loss, and says the open question is whether it is a new adverse effect or a natural consequence of rapid weight loss. Its abstract does not answer that question.[2] - Expert review A 2024 letter analyses trends around "Ozempic face" and rapid facial weight loss on GLP-1 drugs. PubMed lists no abstract, so we cite it only for its subject.[9]
- Case report A 2025 report describes facial filler procedures after semaglutide-associated weight loss. PubMed lists no abstract, so we cite it only for its subject.[11]
- Human observational A 2025 retrospective study of 20 patients with head CT or MR scans taken before and after a GLP-1 prescription reported a median 9.0% drop in total midface volume, mostly in superficial fat, and estimated a loss of about 7% of midface volume for every 10 kg of weight lost. The abstract describes no control group, so the study cannot separate a drug effect from the weight loss itself.[6]
- Expert review Two systematic reviews collect the published reports: a 2025 review of 23 plastic-surgery articles describes facial changes resembling advanced aging with GLP-1 drugs and notes it is limited by study biases, and a 2026 review of 40 human studies lists facial volume loss, dermal thinning and decreased skin elasticity among the reported findings.[7][8]
Measure your own face during a course
If you and your prescriber have started semaglutide, tirzepatide or a similar drug, the only face data that applies to you is your own, taken the same way each time. SoftMaxx AI never suggests taking a GLP-1 for how your face looks.
The free SoftMaxx AI scan gives an overall score, four pillar bands (one of them is Skin) and your single top priority, with one free scan a month. SoftMaxx AI Pro adds the full 11-category breakdown and up to four rescans a month, each showing the change since your last scan.
Read those numbers as your measurements while on a course, not as results of the drug. A scan cannot tell a drug effect from weight change, lighting or camera angle, so rescan in the same light, at the same distance and without makeup, and read the trend over several scans rather than one.
Doses are your prescriber's call. If you have a prescribed dose in milligrams and need it in syringe units, the semaglutide units converter and tirzepatide units converter do the arithmetic and suggest no dose.
Regulatory status (checked 2026-09-30)
- United States (FDA)Semaglutide is FDA-approved as Ozempic and Wegovy (prescription drugs). (DailyMed:
OZEMPIC (semaglutide) injection — Prescribing Information
; DailyMed:WEGOVY (semaglutide) injection; WEGOVY (semaglutide) tablets — Prescribing Information
) Tirzepatide is FDA-approved as Mounjaro and Zepbound (prescription drugs). (DailyMed:MOUNJARO (tirzepatide) injection — Prescribing Information
; DailyMed:ZEPBOUND (tirzepatide) injection — Prescribing Information
) Orforglipron is FDA-approved as Foundayo (prescription drug). (DailyMed:FOUNDAYO (orforglipron) tablets — Prescribing Information
) - CanadaOzempic and Wegovy (semaglutide) have Drug Identification Numbers in Health Canada’s Drug Product Database. (Health Canada:
Health Canada Drug Product Database: OZEMPIC (semaglutide) — Drug Identification Numbers listed
; Health Canada:Health Canada Drug Product Database: WEGOVY (semaglutide) — Drug Identification Numbers listed
) Mounjaro and Zepbound (tirzepatide) have Drug Identification Numbers in Health Canada’s Drug Product Database. (Health Canada:Health Canada Drug Product Database: MOUNJARO (tirzepatide) — Drug Identification Numbers listed
; Health Canada document) - Sport (WADA)Semaglutide is not on the 2026 WADA Prohibited List. (WADA:
World Anti-Doping Code International Standard Prohibited List 2026
) Tirzepatide is not on the 2026 WADA Prohibited List. (WADA:World Anti-Doping Code International Standard Prohibited List 2026
) Orforglipron is not on the 2026 WADA Prohibited List. (WADA:World Anti-Doping Code International Standard Prohibited List 2026
)
Official sources: FDA document 1 · FDA document 2 · FDA document 3 · FDA document 4 · FDA document 5 · Health Canada document 1 · Health Canada document 2 · Health Canada document 3 · WADA: World Anti-Doping Code International Standard Prohibited List 2026
Report a side effect
If something went wrong after using any product, tell a clinician and report it. Reports are how regulators find contaminated or mislabeled products.
- FDA MedWatch (United States)
- Canada Vigilance Program (Canada)
Questions to ask your doctor
SoftMaxx AI gives no doses or prescriptions; take these to a clinician.
- Is the pace of my weight loss one you are comfortable with?
- Is the hair shedding I notice what the label describes, or should we look for another cause?
- Which changes in my face or skin would you want me to report?
- If I am unhappy with how my face is changing, which specialist should I see?
- What should I do if my medicine gets warm or freezes?
Common questions
Does Ozempic change your face?
No supporting study We found no controlled study that measured faces on it. Commentaries tie "Ozempic face" to rapid weight loss depleting facial volume and fat, and one asks whether it is a new drug effect or a natural consequence of rapid weight loss.[1][2]
Is there a "Wegovy face" or "Mounjaro face"?
No supporting study We found no controlled study of faces on Wegovy, Mounjaro or Zepbound either. The Wegovy and Zepbound labels list hair loss and associate it with weight reduction; neither describes a change in facial shape or volume.[3][4]
Does semaglutide cause hair loss?
Drug label The Wegovy label reports hair loss in 3.3% of people on the drug versus 1% on placebo in a pool of three trials, more often in women than in men, and says it was associated with weight reduction.[3]
Can Ozempic face be reversed?
Expert review We found no controlled trial of any approach. A 2023 commentary addressed to facial plastic surgeons says dermal fillers, skin tightening techniques and surgery are used to restore facial volume and manage excess skin, and a 2024 commentary says dermatologists are well positioned to counsel people starting or stopping these drugs.[1][2]
Should I take a GLP-1 to slim my face?
Drug label SoftMaxx AI never suggests taking a GLP-1 for how your face looks. The Wegovy, Zepbound and Foundayo labels describe their use, alongside a reduced-calorie diet and more physical activity, to reduce excess body weight and maintain weight reduction in adults with obesity, or with overweight and a weight-related condition. Whether one fits you is your prescriber's decision.[3][4][5]
References
Every reference below was matched to its PubMed or DOI record (title checked) before publication. "Verified" means the paper exists and is the one named; what it supports is stated next to each claim.
Implications of Ozempic and Other Semaglutide Medications for Facial Plastic Surgeons.
PubMed 37541662 DOINatural Weight Loss or "Ozempic Face": Demystifying A Social Media Phenomenon.
PubMed 38206146 DOIWEGOVY (semaglutide) injection; WEGOVY (semaglutide) tablets — Prescribing Information
SourceZEPBOUND (tirzepatide) injection — Prescribing Information
SourceFOUNDAYO (orforglipron) tablets — Prescribing Information
SourceRadiographic Midfacial Volume Changes in Patients on GLP-1 Agonists.
PubMed 40407186 DOI"Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions.
PubMed 40626110 DOIEffects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review.
PubMed 42162206 DOIThe rise of "Ozempic Face": Analyzing trends and treatment challenges associated with rapid facial weight loss induced by GLP-1 agonists.
PubMed 39098289 DOIThe pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.
PubMed 39693407 DOIFacial Remodeling Addressing Fat Loss and Skin Sagging With Poly- l -Lactic Acid SCA and Hyaluronic Acid Filler After Semaglutide-Associated Prescriptive Weight Loss.
PubMed 40277199 DOI